Impact of Duffy-null Associated Neutropenia on Chemotherapy Dosing
Starting soon · Phase 1/Phase 2
Conditions studied: Solid Tumor Cancer
In brief
The goal of this clinical trial is to: * In Phase 1 (observational) to develop an algorithm for treatment of Duffy-null positive patients for chemotherapy dosing * In Phase 2 (interventional), use the algorithm created in phase 1 to adjust chemotherapy dosing for Duffy-null patients
Key facts
- Study ID
- NCT07743086
- Run by
- Barbara Ann Karmanos Cancer Institute
- People needed
- 886
- Starts
- 2026-09-01
- Expected to finish
- 2029-04-30
- Last updated by the study team
- 2026-08-03
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participant must self-identify as being of Middle Eastern or African descent.
- Participant must be diagnosed with histologically or cytologically confirmed solid organ cancer and be treatment naive.
- Melanoma is allowed; sarcoma is not eligible.
- Secondary malignancies are allowed.
- Participants who have received only surgery alone as treatment are eligible
- Participant must be between the ages of 18-80.
- Participant or their legally authorized representative (LAR) must be able to understand a written informed consent document and be willing to sign it.
You may not qualify if…
- Participants with active and uncontrolled bacterial, viral, or fungal infection requiring IV antibiotics.
- Participants may be eligible for the study if the infection is deemed to be under control per investigator's discretion.
- Participants who have ever received cytotoxic chemotherapy.
- Those who have already started a chemotherapy regimen with moderate likelihood of developing neutropenia will be considered for enrollment at the principal investigator's discretion.
- Participants who are receiving concurrent chemo-radiation treatment.
- Participants who are taking any other investigational drugs.
- Participants who are pregnant or breastfeeding.
- Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to follow the treatment plan.
Where it is running
- Karmanos Cancer Institute — Detroit, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.